GT BIOPHARMA, INC. Retained Earnings
GT BIOPHARMA, INC. (GTBP) had Retained Earnings of -$731.43 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$731.43M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$726.84M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$723.90M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$718.10M; Retained Earnings (Accumulated Deficit) as first filed -$700.78M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$731.43M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$726.84M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | -$723.90M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | -$718.10M 10-Q/A · filed 2026-03-06 | -$700.78M 10-Q · filed 2025-11-14 |
| 2025-06-30 | -$726.26M 10-Q/A · filed 2026-03-06 | -$697.52M 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$696.00M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$695.23M 10-Q/A · filed 2026-03-06 | |
| 2024-09-30 | -$691.45M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$688.04M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$684.33M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$682.07M 10-K · filed 2025-02-21 | |
| 2023-09-30 | -$679.10M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | -$676.69M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | -$674.70M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$674.47M 10-K · filed 2024-03-26 | |
| 2022-09-30 | -$668.88M 10-Q · filed 2022-10-31 | |
| 2022-06-30 | -$662.00M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | -$659.02M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$653.58M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$635.39M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$629.94M 10-Q/A · filed 2021-12-29 | |
| 2021-03-31 | -$625.08M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -$595.80M 10-K · filed 2022-03-28 | -$595.63M 10-K · filed 2021-04-16 |
| 2020-09-30 | -$589.34M 10-K · filed 2021-04-16 | -$580.70M 10-Q · filed 2020-11-13 |
| 2020-06-30 | -$586.46M 10-K · filed 2021-04-16 | -$577.82M 10-Q · filed 2020-08-14 |
| 2020-03-31 | -$569.04M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | -$567.33M 10-K · filed 2021-04-16 | |
| 2019-09-30 | -$565.86M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$535.98M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | -$533.20M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | -$528.68M 10-K · filed 2020-03-27 | |
| 2018-09-30 | -$524.45M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$288.67M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | -$279.59M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | -$269.50M 10-K · filed 2019-03-29 | -$267.90M 10-K · filed 2018-03-01 |
| 2017-09-30 | -$261.87M 10-Q · filed 2017-11-14 | |
| 2017-06-30 | -$129.79M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | -$126.96M 10-Q · filed 2017-04-28 | |
| 2016-12-31 | -$124.65M 10-K · filed 2018-03-01 | |
| 2016-09-30 | -$121.82M 10-Q/A · filed 2018-02-28 | |
| 2016-06-30 | -$118.19M 10-Q/A · filed 2018-02-28 | |
| 2016-03-31 | -$119.73M 10-Q/A · filed 2018-02-28 | |
| 2015-12-31 | -$134.42M 10-K/A · filed 2018-02-28 | -$145.68M 10-K · filed 2016-03-30 |
| 2015-09-30 | -$108.30M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | -$106.61M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | -$133.47M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | -$112.96M 10-K/A · filed 2018-02-28 | |
| 2014-09-30 | -$94.32M 10-Q · filed 2015-01-08 | |
| 2014-06-30 | -$90.10M 10-Q · filed 2015-01-08 | |
| 2014-03-31 | -$89.84M 10-Q · filed 2015-01-08 | |
| 2013-12-31 | -$89.47M 10-K/A · filed 2018-02-28 | |
| 2013-09-30 | -$89.11M 10-Q · filed 2014-12-17 | |
| 2013-06-30 | -$88.80M 10-Q · filed 2014-12-12 | |
| 2013-03-31 | -$88.50M 10-Q · filed 2014-12-10 | |
| 2012-12-31 | -$88.97M 10-K · filed 2015-01-08 | |
| 2012-09-30 | -$88.20M 10-Q · filed 2012-11-21 | |
| 2012-06-30 | -$86.81M 10-Q/A · filed 2012-09-13 | |
| 2012-03-31 | -$84.41M 10-Q · filed 2012-05-21 | |
| 2011-12-31 | -$83.80M 10-K · filed 2014-11-18 | |
| 2011-09-30 | -$82.66M 10-Q · filed 2011-11-21 | |
| 2011-06-30 | -$82.68M 10-Q/A · filed 2011-09-12 | |
| 2010-12-31 | -$80.09M 10-K · filed 2012-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |